This is a type of leukemia that affects young children. It's a serious condition where the bone marrow doesn't make enough healthy blood cells. The leukemia cells are a mix of myeloid and monocytoid cells. It's called 'acute' because it can grow quickly and needs urgent treatment.
Every report comes from a Lived member, sent anonymously.
Have you tried Cytarabine for Acute Myelomonocytic Leukemia?
Acute myelomonocytic leukemia (AMML) is a fast-growing blood cancer and one of the subtypes of acute myeloid leukemia (AML). It starts in the bone marrow, the spongy tissue inside bones where blood cells are made. In AMML, the marrow fills with immature cells that look partly like early granulocytes (infection-fighting white cells) and partly like monocytes, another kind of white cell. These abnormal cells do not work properly, and they crowd out the healthy cells the body needs. Older classification systems call it AML M4. Because normal production falls, people often notice tiredness and breathlessness from anemia (too few red cells), easy bruising or bleeding from low platelets, and infections that linger or keep coming back. The monocytic part of the disease can also spread outside the marrow, so some people develop swollen, sore or bleeding gums, skin lumps or spots, or, less often, involvement of the brain and spinal fluid. Symptoms usually build over weeks rather than months, which is why AMML is treated as an urgent diagnosis. AMML is different from chronic myelomonocytic leukemia (CMML), a slower condition with a similar name. It can occur at any age, including in children and young adults.
AMML, like other forms of AML, begins when bone marrow cells acquire changes in their DNA that let them multiply without maturing. In most people, no cause for those changes can be found, and nothing the person did or did not do explains it. Some factors raise the risk of AML in general. These include older age, smoking, long-term exposure to benzene (a solvent found in some industries and in cigarette smoke), earlier chemotherapy or radiation for another cancer, and a prior bone marrow disorder such as myelodysplastic syndrome. Certain inherited conditions, including Down syndrome and Fanconi anemia, also increase risk. Having a risk factor does not mean someone will develop leukemia, and many people with AMML have none. A common version of AMML includes unusual eosinophils (another type of white cell) and a rearrangement of chromosome 16, written inv(16). This change develops in the leukemia cells themselves; it is not inherited and is not passed on to children.
The first clue is usually a complete blood count, a routine blood test that may show low red cells and platelets along with abnormal or immature white cells called blasts. A blood test can suggest leukemia, but the diagnosis is confirmed with a bone marrow aspiration and biopsy, in which a needle removes a small sample of liquid marrow and bone, usually from the back of the hip, under local anesthetic. In healthy marrow, blasts make up 5% or less of the cells. AML is generally diagnosed when blasts reach at least 20% of the cells in the marrow or blood; certain genetic changes, including inv(16), allow the diagnosis at a lower count. Specialists then use flow cytometry, a test that reads the proteins on the cells' surface, to show that the leukemia has both myeloid and monocytic features. Chromosome and gene testing is a central part of the workup, not an extra. Findings such as inv(16), or mutations in genes like FLT3 or NPM1, help predict how the leukemia will behave and can point to added targeted drugs. A lumbar puncture (spinal tap) is done only if symptoms suggest spread to the brain or spinal fluid.
Treatment usually begins soon after diagnosis because AMML can worsen quickly. For people healthy enough for intensive care, the first phase, called induction, typically combines two chemotherapy drugs: cytarabine given continuously for seven days and an anthracycline such as daunorubicin for the first three (often called 7 + 3). Its goal is remission, meaning no detectable leukemia on standard tests. Most people reach remission after the first round, but induction also wipes out normal blood cells, so it usually means several weeks in the hospital with transfusions and antibiotics. Remission alone is not enough, because leukemia tends to return within months without further treatment. The second phase, consolidation, uses more cycles of chemotherapy, such as high-dose cytarabine, or a stem cell transplant. An allogeneic transplant, using stem cells from a matched donor, lowers the chance of relapse more than chemotherapy alone, but it carries a higher risk of serious complications, so it is usually offered when the leukemia's genetic features suggest a high risk of returning. People whose leukemia has inv(16) often do well with chemotherapy alone and may not need a transplant in first remission. Test results shape the plan. A targeted drug may be added for a specific mutation, such as midostaurin (Rydapt) for FLT3 changes, or gemtuzumab ozogamicin (Mylotarg), an antibody linked to chemotherapy, for leukemia cells carrying the CD33 protein. For people who are older or whose health makes intensive chemotherapy too risky, lower-intensity treatment is an option: azacitidine or decitabine, chemotherapy drugs given in shorter courses, often combined with venetoclax (Venclexta), a pill that helps trigger leukemia cell death. Some people choose supportive care focused on comfort and symptom control. Clinical trials are a standard option to ask about at every stage.
The first months revolve around treatment. Induction and consolidation cycles often involve hospital stays, frequent blood tests, transfusions and periods when white cell counts are very low and infections are a real risk. Fatigue, nausea, mouth sores and hair loss are common during this time. Many people are unable to work for a period, and caregivers often help with transport, meals and time in the hospital. Outlook varies widely, and the most important factors are the leukemia's genetic features, the person's age and their overall health. AMML with inv(16) is classed as favorable risk, with a reasonable chance of cure with intensive chemotherapy. AMML without favorable changes, or that follows an earlier blood disorder or cancer treatment, is harder to treat. Leukemia can return after remission, and that risk is highest in the first few years. After treatment, follow-up involves regular blood counts and sometimes repeat bone marrow tests to watch for relapse, plus care for lasting effects of treatment. People who have had a donor transplant need closer long-term follow-up, including monitoring for graft-versus-host disease, in which donor immune cells attack the body's tissues.
See a doctor soon if you have tiredness, paleness, breathlessness, easy bruising, swollen or bleeding gums, or infections that keep returning, especially when these persist or worsen over a few weeks; a blood count is a simple first step. During and after treatment, call your care team right away for a fever of 100.5 F (38 C) or higher, shaking chills, or bleeding that will not stop, because infections and bleeding can become serious quickly when blood counts are low. Ask your team in advance whether they want you to call or go straight to the hospital for a fever. Sudden confusion, slurred speech, weakness on one side of the body, severe shortness of breath or sudden vision loss can mean leukemia cells are blocking small blood vessels, and need emergency care immediately.
Last reviewed • Oct 2026
Educational content, not medical advice.
Share what living with Acute Myelomonocytic Leukemia is like, what's helped you, or ask the community a question.